Top Story Today
A Paralyzed Patient in China Can Now Buy a Brain Implant. Neuralink Is Still in Trials.
China just granted the world's first commercial approval for an invasive brain-computer interface, leapfrogging every U.S. competitor to a milestone many thought was years away. The device, called NEO, reads neural signals from a sensor placed on the brain's surface and translates them into commands for a robotic glove, letting paralyzed patients grasp objects with their thoughts. Across 36 procedures, every single patient improved. Beijing's fast-track regulatory infrastructure, which treats BCI as a national priority alongside AI and quantum computing, gave Neuracle Technology the runway to beat Neuralink to market.
Why it matters: This approval reshapes the global neurotechnology race and could pressure the FDA to accelerate its own BCI pathways. With China's BCI market projected to hit $800 million by 2027, the competitive dynamics for Neuralink, Synchron, and Blackrock Neurotech just changed overnight.
Read more →Clinical Wins and Wagers
Vertex Dropped $5 Billion on a Kidney Drug. The Bet Just Landed.
Vertex's stock hit a 44-week high after povetacicept, the drug it acquired for $4.9 billion, crushed its Phase 3 trial in IgA nephropathy. The drug cut urinary protein by 52%, slashed the disease-causing antibody by 79%, and cleared blood from urine in 85% of patients. With an FDA submission planned by month's end and a priority review voucher in hand, approval could come as early as November 2026.
Read more →Biogen's Once-a-Year SMA Shot Just Posted Data That Turns Heads
All 24 children in Biogen's Phase 1b trial for salanersen improved on at least one motor function measure, and half hit brand-new milestones like sitting or standing. The drug, a once-yearly successor to Spinraza, reduced a key nerve-damage biomarker by 75% in six months. Three Phase 3 trials are launching this year, targeting everyone from newborns to adults.
Read more →Clinical Setbacks and Survival Mode
Immutep Lost 90% of Its Value Before Lunch
An independent committee pulled the plug on Immutep's Phase 3 lung cancer trial after determining the drug would never hit its endpoints. Shares cratered roughly 89% on the ASX in a single session. The failure adds to a brutal streak of late-stage immunotherapy collapses, particularly around checkpoint targets like LAG-3 and TIGIT that keep looking great early and falling apart late.
Read more →Inovio Has $58M, 112 Employees, and Seven Months to Save Itself
Inovio cut 16% of its workforce after the FDA questioned whether its rare disease drug INO-3107 qualifies for accelerated approval. The company's cash runs out right around the FDA's October decision date. For the 17,000 Americans with recurrent respiratory papillomatosis (a throat tumor disease with only one approved treatment), Inovio's candidate represents an important additional option.
Read more →Devices and Regulatory Shakeups
174,000 Insulin Pumps Just Got Recalled. The Defect Is Alarming.
Insulet recalled over 174,000 Omnipod 5 pods after a torn internal tube caused insulin to pool inside the device instead of reaching patients. Eighteen serious adverse events were reported, including hospitalizations for diabetic ketoacidosis. It's not the company's first recall; a 2023 Class 1 recall also affected Omnipod products.
Read more →One FDA Official Quit. Gene Therapy Stocks Went Berserk.
uniQure surged 26% in a single day on news that CBER director Vinay Prasad is leaving the FDA after a chaotic 10-month tenure that included multiple therapy rejections, a firing-and-rehiring, and a workplace toxicity investigation. uniQure rallied on hopes that the next director will be friendlier to accelerated approvals.
Read more →